Rottlerin inhibits PKCδ to attenuate pulmonary fibrosis by suppressing NLRC4/ASC-mediated pyroptosis

Our findings reveal that Rottlerin alleviates PF by targeting PKCδ to suppress NLRC4/ASC-mediated pyroptosis and inflammation. This study innovatively focused on the anti-pulmonary fibrosis strategy targeting the PKCδ-NLRC4 axis, revealed an important link in the inflammation-fibrosis transition, provided evidence on Rottlerin's anti-fibrotic effects and identifies a novel therapeutic strategy for PF.